SCHEMBL4998799

SCHEMBL4998799

CCOP(=O)(CBr)Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
BCHE P06276 1/20 0.52
ACHE P22303 1/20 0.52
TSHR P16473 2/20 0.51
ALDH1A1 P00352 2/20 0.51
CYP3A4 P08684 1/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
AKR1C3 P42330 1/20 0.48
KDM4E B2RXH2 1/20 0.43
CCNT1 O60563 2/20 0.43
CDK9 P50750 2/20 0.43
IDO1 P14902 2/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KCNH2 Q12809 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030185 0.88 CA1 (0.55) CA1CA2BCHEACHETSHR
SCHEMBL78561 0.81 CA1 (0.58) CA1CA2BCHEACHETSHR
SCHEMBL915525 0.80 AKR1C3 (0.59) CA1CA2BCHEACHETSHR
SCHEMBL2031961 0.80 CA1 (0.56) CA1CA2BCHEACHETSHR
SCHEMBL4131256 0.79 CA1 (0.55) CA1CA2BCHEACHETSHR
SCHEMBL5002879 0.76 CA2 (0.43) CA1CA2BCHEACHETSHR
SCHEMBL5008225 0.75 KCNJ1 (0.52) CA1CA2BCHEACHETSHR
SCHEMBL28623371 0.74 ACHE (0.50) CA1CA2BCHEACHETSHR
SCHEMBL1542660 0.74 CA1 (0.65) CA1CA2BCHEACHETSHR
SCHEMBL1542484 0.73 CA1 (0.55) CA1CA2BCHEACHETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
EP-1812453-A1 METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES Therapharm GmbH (CH) 2007-08-01 EP disclosed
WO-2006045546-A1 METHOD OF PREPARING OR SYNTHESIZING POLYAZAMACROCYCLE DERIVATIVES THERAPHARM GMBH (CH) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives POLI, PARP1, DHPS CA1 3452/4885CA2 4117/4885BCHE 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.